Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. SER
stocks logo

SER

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax
Wall Street analysts forecast SER stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SER is 13.00 USD with a low forecast of 11.00 USD and a high forecast of 15.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
Wall Street analysts forecast SER stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SER is 13.00 USD with a low forecast of 11.00 USD and a high forecast of 15.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 3.470
sliders
Low
11.00
Averages
13.00
High
15.00
Current: 3.470
sliders
Low
11.00
Averages
13.00
High
15.00
H.C. Wainwright
H.C. Wainwright
Buy
initiated
$15
2025-07-14
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$15
2025-07-14
initiated
Buy
Reason
H.C. Wainwright initiated coverage of Serina Therapeutics with a Buy rating and $15 price target. The firm says Serina is an emerging biopharmaceutical company focused on developing next-generation versions of existing active pharmaceutical ingredients.
Jones Trading
Justin Walsh
Strong Buy
Initiates
$11
2025-03-11
Reason
Jones Trading
Justin Walsh
Price Target
$11
2025-03-11
Initiates
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Serina Therapeutics Inc (SER.A) is -1.87, compared to its 5-year average forward P/E of -1.31. For a more detailed relative valuation and DCF analysis to assess Serina Therapeutics Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-1.31
Current PE
-1.87
Overvalued PE
0.17
Undervalued PE
-2.80

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

SER News & Events

Events Timeline

(ET)
2025-11-13
06:11:33
Serina Therapeutics announces Q3 earnings per share of 45 cents, compared to 13 cents in the previous year.
select
2025-11-03 (ET)
2025-11-03
06:12:02
Serina Therapeutics Announces FDA Imposes Clinical Hold on IND for SER-252
select
2025-09-09 (ET)
2025-09-09
15:28:40
Serina Therapeutics reveals deal for potential access to $20M in funding
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.5
11-13Newsfilter
Serina Therapeutics Announces Financial Results and Business Highlights for Q3 2025

  • Financial Results: Serina Therapeutics reported a net loss of $4.6 million for Q3 2025, with operating expenses increasing to $6.4 million, driven by higher research and development costs. The company has $8.6 million in cash and equivalents as of September 30, 2025.

  • Regulatory Progress: The FDA has supported Serina's plan to advance its Parkinson's disease candidate, SER-252, under a 505(b)(2) NDA pathway, although the IND is currently on clinical hold pending further information.

  • Funding Initiatives: Serina secured up to $20 million in funding through a convertible note and warrant financing agreement, with the first tranche of $5 million already drawn. Additionally, the company has an ATM equity program allowing for the sale of up to $13.3 million in common stock.

  • Pipeline Development: The company is advancing SER-270 for tardive dyskinesia and plans to complete formulation optimization and pre-IND activities in 2026, while also enhancing stakeholder communications through a new corporate platform.

[object Object]
Preview
9.0
11-03NASDAQ.COM
What’s Causing the Decline of Serina Therapeutics Stock in Pre-market Trading?

  • FDA Clinical Hold: The FDA has placed a clinical hold on Serina Therapeutics' Investigational New Drug application for SER-252, which is intended for advanced Parkinson's disease, due to requests for additional information regarding an excipient in the formulation.

  • Company Response: Serina Therapeutics anticipates receiving a formal clinical-hold letter from the FDA within 30 days and plans to update stakeholders once they have clarified next steps and timelines with the agency.

  • Market Reaction: Following the announcement of the clinical hold, shares of Serina Therapeutics fell by 8% in pre-market trading on Monday.

  • Source Disclaimer: The views expressed in the article are those of the author and do not necessarily reflect the opinions of Nasdaq, Inc.

[object Object]
Preview
8.5
10-07Newsfilter
Serina Therapeutics Secures Initial $5 Million Funding to Advance SER-252 Registrational Trial for Parkinson's Disease

  • Financing Agreement: Serina Therapeutics has received the first $5 million tranche of a financing agreement that could total up to $20 million, aimed at advancing the registrational trial of SER-252 for advanced Parkinson's disease.

  • Clinical Trial Progress: The company has submitted an Investigational New Drug (IND) application to the FDA and obtained HREC approval in Australia, with plans to initiate a global trial in Q4 2025, focusing on the safety and efficacy of SER-252.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Serina Therapeutics Inc (SER) stock price today?

The current price of SER is 3.47 USD — it has decreased -0.29 % in the last trading day.

arrow icon

What is Serina Therapeutics Inc (SER)'s business?

Serina Therapeutics Inc. is a clinical-stage biotechnology company developing a pipeline of wholly owned drug product candidates to treat neurological diseases and other indications. The Company's POZ Platform provides the potential to improve the integrated efficacy and safety profile of multiple modalities including small molecules, RNA-based therapeutics and antibody-based drug conjugates (ADCs). Its proprietary POZ technology is based on a synthetic, water soluble, low viscosity polymer called poly(2-oxazoline). Its POZ technology is engineered to provide greater control in drug loading and more precision in the rate of release of attached drugs delivered via subcutaneous injection. SER-252 is the Company’s lead candidate for advanced Parkinson’s disease. SER-252 is an investigational apomorphine therapy developed with its POZ platform and designed to provide continuous dopaminergic stimulation.

arrow icon

What is the price predicton of SER Stock?

Wall Street analysts forecast SER stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SER is 13.00 USD with a low forecast of 11.00 USD and a high forecast of 15.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Serina Therapeutics Inc (SER)'s revenue for the last quarter?

Serina Therapeutics Inc revenue for the last quarter amounts to 0.00 USD, decreased -100.00 % YoY.

arrow icon

What is Serina Therapeutics Inc (SER)'s earnings per share (EPS) for the last quarter?

Serina Therapeutics Inc. EPS for the last quarter amounts to -0.44 USD, decreased -438.46 % YoY.

arrow icon

What changes have occurred in the market's expectations for Serina Therapeutics Inc (SER)'s fundamentals?

The market is revising No Change the revenue expectations for SER for , with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -31.83%.
arrow icon

How many employees does Serina Therapeutics Inc (SER). have?

Serina Therapeutics Inc (SER) has 12 emplpoyees as of December 05 2025.

arrow icon

What is Serina Therapeutics Inc (SER) market cap?

Today SER has the market capitalization of 37.00M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free